George Yang, MD

Cancer Focus:
Esophageal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Throat Cancer, Thyroid Cancer, Tongue Cancer

Dr. George Yang is an Assistant Member in the Section of Head and Neck and Endocrine Oncology in the  Moffitt Cancer Center Department of Radiation Oncology. Dr. Yang received his MD from the University of South Florida, Morsani College of Medicine. He completed a Radiation Oncology Residency at Moffitt Cancer Center/University of South Florida, where he also served as Chief Resident. Dr. Yang’s clinical interests focus on the use of radiotherapy techniques such as intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) to treat patients with head/neck and endocrine cancers. His research interests focus on the use of multi-modality therapy, including radiation therapy, in the treatment of locally advanced and recurrent head and neck cancers. He is also developing clinical trials in the pursuit of personalizing radiation therapy as part of the Departmental FORT (Future of Radiation Therapy) research program. 

Education & Training

Residency:

• University of South Florida/Moffitt Cancer Center - Radiation Oncology

Medical School:

• University of South Florida Morsani College of Medicine - MD

Clinical Trial 22313
Phase 2 Trial of Adaptive Radiotherapy Boost for Head and Neck Squamous Cell Carcinomas
Condition: Head & Neck
Intervention: Radiotherapy ()
Status: Open

Clinical Trial 23441
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer
Condition: Head & Neck
Intervention: Ipatasertib (); cisplatin ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Caudell J, Echevarria M, Yang G, Kim Y, Kirtane K, Kish J, Muzaffar J, Zahid M, Chung C, Enderling H. Phase 2 Prospective Trial of Personalized Radiation Therapy Fractionation in Human Papillomavirus Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2026 Jan. Pubmedid: 41519405.
• Echevarria M, Park R, Caudell JJ, Kim Y, Yang GQ, Kirtane K, Chaudhary R, Kumar S, Amelio AL, Giuliano AR, Chung CH. Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy. Cancer Res Commun. 2025 Jul.5(7):1194-1202. Pubmedid: 40643202. Pmcid: PMC12281097.
• Bryant JM, Mills MN, Liveringhouse C, Palm R, Druta M, Brohl A, Reed DR, Johnstone PA, Miller JT, Latifi K, Feygelman V, Yang GQ, Naghavi AO. Hypofractionated accelerated radiation dose-painting (HARD) improves outcomes in unresected soft-tissue sarcoma. Radiother Oncol. 2025 Jan.202:110644. Pubmedid: 39571685.
• Sousa LG, Edward Bates J, Anand P, Caudell JJ, Colevas AD, Runge CL, Sharon JD, Awan M, Beadle BM, Choe JH, Gidley PW, Harari PM, Henson C, Katzel JA, Lee NY, Mcdowell L, Mell LK, Nader ME, Rudra S, Wang K, Yang G, Yom SS, Wise-Draper TM. Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience. J Natl Cancer Inst. 2025 Dec. Pubmedid: 41344314. Pmcid: PMC12849746.
• LaVigne AW, Doss VL, Berizzi D, Johnston FM, Kiess AP, Kirtane KS, Moghanaki D, Roumeliotis M, Yang GQ, Viswanathan AN. The History and Future of Multidisciplinary Cancer Care. Semin Radiat Oncol. 2024 Oct.34(4):441-451. Pubmedid: 39271279.
• Mills M, Miller J, Liveringhouse C, Bryant JM, Kawahara Y, Feygelman V, Latifi K, Yang G, Johnstone PA, Naghavi AO. Novel Postoperative Hypofractionated Accelerated Radiation Dose-Painting Approach for Soft Tissue Sarcoma. Adv Radiat Oncol. 2024 Mar.9(3):101391. Pubmedid: 38495036. Pmcid: PMC10943519.
• Naghavi AO, Bryant JM, Kim Y, Weygand J, Redler G, Sim AJ, Miller J, Coucoules K, Michael LT, Gloria WE, Yang G, Rosenberg SA, Ahmed K, Bui MM, Henderson-Jackson EB, Lee A, Lee CD, Gonzalez RJ, Feygelman V, Eschrich SA, Scott JG, Torres-Roca J, Latifi K, Parikh N, Costello J. Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma. BMC Cancer. 2024 Apr.24(1):437. Pubmedid: 38594603. Pmcid: PMC11003059.
• Bryant JM, Mills MN, Yang GQ, Liveringhouse C, Palm R, Johnstone PA, Miller JT, Latifi K, Feygelman V, Naghavi AO. Novel Definitive Hypofractionated Accelerated Radiation Dose-painting (HARD) for Unresected Soft Tissue Sarcomas. Adv Radiat Oncol. 2024 Apr.9(4):101447. Pubmedid: 38778821. Pmcid: PMC11110037.
• Liveringhouse CL, Palm RF, Bryant JM, Yang GQ, Mills MN, Figura ND, Ahmed KA, Mullinax J, Gonzalez R, Johnstone PA, Naghavi AO. Neoadjuvant Simultaneous Integrated Boost Radiation Therapy Improves Clinical Outcomes for Retroperitoneal Sarcoma. Int J Radiat Oncol Biol Phys. 2023 Sep.117(1):123-138. Pubmedid: 36935026.
• Liveringhouse CL, Yang GQ, Naghavi AO. In Reply to Kahvecioglu et al. Int J Radiat Oncol Biol Phys. 2023 Sep.117(1):285-286. Pubmedid: 37574241.
• Echevarria MI, Yang GQ, Chen DT, Kirtane K, Russell J, Kish J, Muzaffar J, Otto K, Padhya T, McMullen C, Patel K, Chung CH, Caudell JJ. Phase 1 Dose Escalation of Stereotactic Body Radiation Therapy and Concurrent Cisplatin for Reirradiation of Unresectable, Recurrent Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2023 Oct.117(2):341-347. Pubmedid: 37105404.
• Palm RF, Liveringhouse CL, Gonzalez RJ, Bui MM, Binitie O, Yang GQ, Naghavi AO. Effect of Favorable Pathologic Response After Neoadjuvant Radiation Therapy Alone in Soft-tissue Sarcoma. Adv Radiat Oncol. 2023 Jan.8(1):101086. Pubmedid: 36483058. Pmcid: PMC9723307.
• Nasser N, Yang GQ, Koo J, Bowers M, Greco K, Feygelman V, Moros EG, Caudell JJ, Redler G. A head and neck treatment planning strategy for a CBCT-guided ring-gantry online adaptive radiotherapy system. J Appl Clin Med Phys. 2023 Dec.24(12):e14134. Pubmedid: 37621133. Pmcid: PMC10691641.
• Yang GY, Caudell JJ. Chemotherapy Only For High-risk Features. Int J Radiat Oncol Biol Phys. 2022 Sep.114(1):13. Pubmedid: 35964626.
• Yuan Z, Yang GQ, Ahmed KA, Torres-Roca JF, Spiess PE, Johnstone PA. Radiation therapy in the management of the inguinal region in penile cancer: What's the evidence?. Urol Oncol. 2022 Jun.40(6):223-228. Pubmedid: 32482510.
• Yang G, Yuan Z, Ahmed K, Welsh EA, Fulp WJ, Gonzalez RJ, Mullinax JE, Letson D, Bui M, Harrison LB, Scott JG, Torres-Roca JF, Naghavi AO. Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization. Transl Oncol. 2021 Oct.14(10):101165. Pubmedid: 34246048. Pmcid: PMC8274330.
• Frazer ML, Yang G, Felder S, McDonald J, Sanchez J, Dessureault S, Imanirad I, Carballido E, Kim RD, Hoffe SE, Frakes JM. Determining Optimal Follow-up for Patients With Anal Cancer Following Chemoradiation. Am J Clin Oncol. 2020 May.43(5):319-324. Pubmedid: 32028341.
• Yang GQ, Harrison LB. A Hard Target Needs a Sharper DaRT. Int J Radiat Oncol Biol Phys. 2020 May.107(1):152-153. Pubmedid: 32277913.
• Parekh AD, Culbert MM, Brower JV, Yang GQ, Golden DW, Amdur RJ. Nonclinical Time in U.S. Radiation Oncology Residency Programs: Number of Months and Resident Opinion of Value. Int J Radiat Oncol Biol Phys. 2020 Mar.106(4):683-689. Pubmedid: 32092341.
• Yang G, Mills M, Kim Y, Figura NB, Doyle C, Oliver D, Grass GD, Robinson T, Chavez J, Kim S. Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation. Blood Cancer J. 2020 Jan.9(12):104. Pubmedid: 31894139. Pmcid: PMC6938796.
• Naghavi AO, Kim Y, Yang GQ, Ahmed KA, Caudell JJ. Alterations in genetic pathways following radiotherapy for head and neck cancer. Head Neck. 2020 Feb.42(2):312-320. Pubmedid: 31833149. Pmcid: PMC7771332.
• Palm RF, Oliver DE, Yang GQ, Abuodeh Y, Naghavi AO, Johnstone PAS. The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: An analysis of the National Cancer Data Base. Cancer. 2019 Feb.125(4):642-651. Pubmedid: 30644538.
• Mills MN, Yang GQ, Oliver DE, Liveringhouse CL, Ahmed KA, Orman AG, Laronga C, Hoover SJ, Khakpour N, Costa RLB, Diaz R. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis. Eur J Cancer. 2018 Jul.98:48-58. Pubmedid: 29870876.
• Oliver DE, Donnelly OG, Grass GD, Naghavi AO, Yang GQ, Dilling TJ, Perez BA. Extracranial metastatic burden in extensive-stage small cell lung cancer: implications for prophylactic cranial irradiation. J Thorac Dis. 2018 Jul.10(7):4321-4327. Pubmedid: 30174879. Pmcid: PMC6106034.
• Yang GQ, Mhaskar R, Rishi A, Naghavi AO, Frakes JM, Almhanna K, Fontaine J, Pimiento JM, Hoffe SE. Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy. Dis Esophagus. 2018 Dec.32(8). Pubmedid: 30597022.
• Yuan Z, Fromm A, Ahmed KA, Grass GD, Yang GQ, Oliver DE, Dilling TJ, Antonia SJ, Perez BA. Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the Lung. J Thorac Oncol. 2017 Sep.12(9):e135-e136. Pubmedid: 28502722.
• Yang G, Strom TJ, Wilder RB, Shrinath K, Mellon EA, Fernandez DC, Biagioli MC. Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes. Int Braz J Urol. 2015 May.41(3):435-441. Pubmedid: 26200536. Pmcid: PMC4752135.
• Holliday EB, Yang G, Jagsi R, Hoffman KE, Bennett KE, Grace C, Zietman AL. Fate of manuscripts rejected from the Red Journal. Int J Radiat Oncol Biol Phys. 2015 Jan.91(1):3-10. Pubmedid: 25835616.
• Davis GR, Illig KA, Yang G, Nguyen TH, Shames ML. An approach to EVAR simulation using patient specific modeling. Ann Vasc Surg. 2014 Oct.28(7):1769-1774. Pubmedid: 24911807.